Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa M. Rimsza, Jonathan W. Friedberg

Blood (2019) 133 (16): 1762–1765.

https://doi.org/10.1182/blood-2018-08-870915

Published: 2019

Includes: Supplemental data

Journal Articles

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

Blood (2014) 124 (21): 4434.

https://doi.org/10.1182/blood.V124.21.4434.4434

Published: 2014

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth Christian, MD, John Kuruvilla, MD, Sonali Smith, MD, Pierluigi Porcu, MD, Amy S. Ruppert, MAS, John C. Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 4476.

https://doi.org/10.1182/blood.V124.21.4476.4476

Published: 2014

Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood (2011) 117 (22): 5827–5834.

https://doi.org/10.1182/blood-2010-10-312603

Published: 2011

Journal Articles

Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis

Sonali Smith, MD, Linda J Burns, MD, Koen van Besien, MD, Jennifer LeRademacher, PhD, Wensheng He, PhD, Ginna G. Laport, MD, Silvia Montoto, MD, David G Maloney, MD, Phd, Parameswaran Hari, MD

Blood (2010) 116 (21): 689.

https://doi.org/10.1182/blood.V116.21.689.689

Published: 2010

Journal Articles

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L Allen, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, Ian D. Lewis, MD, Miles Prince, MD, MRACMA, FRACP, FRCPA, Sonali Smith, MD, Elaine S Jaffe, MD, Susan Bates, MD

Blood (2009) 114 (22): 1657.

https://doi.org/10.1182/blood.V114.22.1657.1657

Published: 2009

Journal Articles

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Daniel A Pollyea, MD, Sonali Smith, MD, Nathan Fowler, MD, Thomas E Boyd, MD, Ashley M Smith, BA, Mint Sirisawad, BS, Lee A Honigberg, PhD, Ahmed Hamdy, MD, Ranjana Advani, MD

Blood (2009) 114 (22): 3713.

https://doi.org/10.1182/blood.V114.22.3713.3713

Published: 2009

Journal Articles

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson

Blood (2009) 114 (22): 933.

https://doi.org/10.1182/blood.V114.22.933.933

Published: 2009

Journal Articles

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Andrew M. Evens, DO, MS, Kevin A. David, MD, Irene Helenowski, PhD, Sheetal M. Kircher, MD, Lauren Mauro, MD, Alla Gimelfarb, MD, Koen Van Besien, MD, Elise Hattersley, MD, Beverly P Nelson, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jamile M. Shammo, MD, FASCP, Scott E. Smith, MD, PhD, Sonali Smith, MD

Blood (2008) 112 (11): 1776.

https://doi.org/10.1182/blood.V112.11.1776.1776

Published: 2008

Journal Articles

Phase II Study of GM-CSF, IL-2 and Rituximab Immunomodulation Following Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Lymphomas

Xavi er Poiré, MD, Justin Kline, Kathy Conner, RN, Todd M. Zimmerman, MD, Koen van Besien, MD, Sonali Smith, MD

Blood (2008) 112 (11): 5433.

https://doi.org/10.1182/blood.V112.11.5433.5433

Published: 2008

Journal Articles

A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

Alexandra M. Levine, MD, Lee Schwartzberg, MD, Sonali Smith, MD, Robert Belt, Raymond Knight, Dawn Carlson, Richard Hippensteel, Brad Kahl

Blood (2005) 106 (11): 1493.

https://doi.org/10.1182/blood.V106.11.1493.1493

Published: 2005

Journal Articles

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Koen W. van Besien, MD, Andrew Artz, MD, Sonali Smith, MD, Elizabeth Rich, MD, Lucy Godley, MD, PhD, Demetria Jones, Paula Del Cerro, RN, Diane Switzer, RN, Brendan Casey, Olatoyosi Odenike, MD, Michael Thirman, MD, Chris Daugherty, MD, Todd M. Zimmerman, MD, Richard Larson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 2321.

https://doi.org/10.1182/blood.V104.11.2321.2321

Published: 2004

Journal Articles

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection

Koen Van Besien, Sonali Smith, John Anastasi, Richard Larson, Michael Thirman, Toyosi Odenike, Wendy Stock

Blood (2004) 103 (11): 4373–4374.

https://doi.org/10.1182/blood-2004-02-0583

Published: 2004

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Phase II Study of GM-CSF, IL-2 and Rituximab Immunomodulation Following Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Lymphomas

A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only